Please check the following:
- {{error.value}}
FREE membership
FREE membership
Join InvestSMART today
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
Please enter the 5 digit verification code sent to "{{user.DayPhone}}" Change number
We cannot send you a verification code via SMS to "{{user.DayPhone}}" Change number
{{ completedStep1 ? 'Start your free 15 day trial now' : content.trialHeading.replace('{0}', user.FirstName) }}
Please enter your mobile number and press send to receive a text message with a verification code.
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
Thank you
We have sent you an email with the details of your registration.
Purchase order
Sign up
OR
Sign up with
Login with
By continuing, you agree to our
Log in
Your account has been locked.
Please contact our {{ isPMAUser ? 'Portfolio Services' : 'Customer Service' }} Team:
- Call 1300 880 160
Looks you are already a member. Please enter your password to proceed
OR
Sign up with
Login with
By continuing, you agree to our
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Log in
Your account has been locked.
Please contact our {{ isPMAUser ? 'Portfolio Services' : 'Customer Service' }} Team:
- Call 1300 880 160
OR
Sign up with
Login with
By continuing, you agree to our
Upgrade Today
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
{{eventFunction.Name}}
{{eventFunction.EventTypeName}}
{{eventFunction.StartDate}}
{{eventFunction.EventTimings}}
{{eventFunction.VenueName}}
{{ t.Cost === 0 ? "FREE" : "$" + t.Cost.toFixed(2) }}
Quantity *
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
Check your inbox
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
NeuroScientific Biopharmaceuticals Ltd (ASX:NSB)
ALERT: Price-sensitive ASX Announcement for NSB
Current share price for NSB : $0.058 -0.006 (-9.38%)+
Announcement
Release
28 Jul 2026 10:02AM
Price at Release
$0.064
Full Release
Summary
NeuroScientific Biopharmaceuticals Ltd announced positive developments in their ongoing activities targeting immune-mediated inflammatory diseases. During the quarter ending 30 June 2026, the company focused on clinical trials and manufacturing process advancements for their StemSmart™ technology. Five patients with fistulising Crohn's Disease showed clinical improvement under the Special Access Scheme. The company is preparing for Phase 2 clinical trials in Australia and the US and progressing the technology transfer of StemSmart™ production to Q-Gen Cell Therapeutics. Financially, the company reported a cash balance of $4.6M and net cash used for operating activities of $1.055M, mainly for research and development. The company plans to continue focusing on clinical programs and investor engagement in the coming financial year.
Key Points
- Clinical response in 80% of Crohn's patients treated with StemSmart™
- Initiation of Phase 2 clinical trials for fistulising Crohn’s Disease
- Technology transfer to Q-Gen Cell Therapeutics on schedule
- $4.6M cash position as of 30 June 2026
- Net cash used for operating activities: $1.055M
- Preparation of pre-IND briefing package for US FDA
- Engagement with investors and market on clinical trial progress
- Out-licensing opportunities for EmtinB™ asset
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
